Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Loratadine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    11 result(s) found for: Loratadine. Displaying page 1 of 1.
    EudraCT Number: 2020-000702-29 Sponsor Protocol Number: LORALAM-2020 Start Date*: 2021-06-07
    Sponsor Name:IDIBELL (Institut d’Investigació Biomédica de Bellvitge)
    Full Title: Phase-II randomized clinical trial to evaluate the effect of Loratadine associated with Rapamune on Lymphagioleiomyomatosis (LAM).
    Medical condition: EFFECT OF LORATADINE ON LYMPHANGIOLEIOMYOMATOSIS
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049459 Lymphangioleiomyomatosis PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-005404-13 Sponsor Protocol Number: CIGE025ADE05 Start Date*: 2007-01-23
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized, 24-week, double-blind, placebo-controlled, parallel-group, multicenter study to assess the efficacy and safety of Omalizumab in adult patients with chronic urticaria who exhibit IgE a...
    Medical condition: chronic urticaria
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002805-21 Sponsor Protocol Number: D2530C00011 Start Date*: 2005-09-25
    Sponsor Name:AstraZeneca AB
    Full Title: A randomized, double-blind, placebo controlled, three-way crossover study exploring the efficacy of AZD3778 compared with placebo and an oral antihistamine (loratadine) in a model of seasonal aller...
    Medical condition: This is a Phase II trial (Proof of Principle) in volunteer rhinitis subjects utilising a seasonal model of rhinitis and challenge agent
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001291-12 Sponsor Protocol Number: SPON CU 085 Start Date*: 2005-04-27
    Sponsor Name:Cardiff University
    Full Title: Histamine Release and Implications of H1- and H2- Blockade in Adult Cardiac Surgery - A Randomised Controlled Study
    Medical condition: During cardiac surgery involving the use of cardiopulmonary bypass histamine is released in the blood. Histamine release has been related to an increased incidence of perioperative dysrhythmias and...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-002284-13 Sponsor Protocol Number: CRx-197-003 Start Date*: 2009-01-19
    Sponsor Name:CombinatoRx, Incorporated
    Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, CONTROLLED STUDY TO ASSESS THE ANTI-INFLAMMATORY PROPERTIES OF TOPICAL CRX-197 IN LESIONAL SKIN OF ADULT SUBJECTS WITH MILD TO MODERATE ATOPIC DERMATITIS
    Medical condition: mild to moderate atopic dermatitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005024-42 Sponsor Protocol Number: TCP-102 Start Date*: 2014-06-18
    Sponsor Name:Menlo Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Study of the Neurokinin-1 Receptor Antagonist VPD-737 in Subjects with Prurigo Nodularis
    Medical condition: Pruritus nodularis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004216-31 Sponsor Protocol Number: CIGE025E2201 Start Date*: 2012-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004916-79 Sponsor Protocol Number: SMART_10 Start Date*: 2013-02-26
    Sponsor Name:Lofarma S.p.A.
    Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS® Grass tablets for patients with grass pollen-induced allergic rhinoconjunctivitis, a phase III study
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002129-43 Sponsor Protocol Number: SMART_7 Start Date*: 2013-12-09
    Sponsor Name:Lofarma S.p.A.
    Full Title: Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS®Birch-Alder tablets for patients with tree pollen-induced allergic rhinoconjunctivitis A Phase III study
    Medical condition: Patients suffering from allergic rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004887-31 Sponsor Protocol Number: OPN-FLU-NP-3102 Start Date*: 2014-11-04
    Sponsor Name:OptiNose US, Inc
    Full Title: A 16-Week RaNdomized, Double-Blind, Placebo-Controlled, PArallel-Group, Multicenter Study EValuatInG the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of FluticAsone Prop...
    Medical condition: Bilateral Nasal Polyposis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10028754 Nasal polyp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004886-34 Sponsor Protocol Number: OPN-FLU-NP-3101 Start Date*: 2014-03-26
    Sponsor Name:OptiNose US, Inc
    Full Title: A 16-Week RaNdomized, Double-Blind, Placebo-Controlled, PArallel-Group, Multicenter Study EValuatInG the Efficacy and Safety of Intranasal Administration of 100, 200, and 400 μg of FluticAsone Prop...
    Medical condition: Bilateral Nasal Polyposis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004855 10028754 Nasal polyp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 03:35:34 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA